NUVATION BIO INC.
1500 Broadway, Suite 1401
New York, New York 10036
March 29, 2021
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
RE: | Nuvation Bio Inc. |
Registration Statement on Form S-1 |
File No. 333-254176 |
Ladies and Gentlemen:
Nuvation Bio Inc. (the Registrant) hereby requests that the U.S. Securities and Exchange Commission (the Commission) cause the Registrants above-referenced Registration Statement on Form S-1 to become effective on March 31, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth L. Guernsey and John T. McKenna of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth L. Guernsey of Cooley LLP, counsel to the Registrant, at (415) 693-2091, or in his absence, John T. McKenna at (650) 843-5059.
Very truly yours,
NUVATION BIO INC. | ||
By: | /s/ Jennifer Fox | |
Name: | Jennifer Fox | |
Title: | Chief Financial Officer |
cc: | David Hung, M.D., Nuvation Bio Inc. |
Kenneth L. Guernsey, Cooley LLP |
John T. McKenna, Cooley LLP |